GLB 003
Alternative Names: GLB-003Latest Information Update: 29 Dec 2023
At a glance
- Originator GluBio Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 15 Dec 2023 Early research in Solid tumours in USA (unspecified route), prior to December 2023 (GluBio Therapeutics pipeline, December 2023)